Costs of an outbreak of meticillin-resistant Staphylococcus aureus

Journal of Hospital Infection

Volumn 66, Issue 1, 2007, Pages 22-28

  Kanerva, M ^a,b   Blom, M ^a,c,d   Tuominen, U ^a   Kolho, E ^a   Anttila, V J ^a   Vaara, M ^b   Virolainen Julkunen, A ^a   Lyytikainen O ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ACADEMY OF FINLAND   (Finland)

^d JORVI HOSPITAL   (Finland)

Author keywords

Cost analysis; Meticillin resistant Staphylococcus aureus; Outbreak

Indexed keywords

METICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; EPIDEMIC; FINLAND; HEALTH CARE COST; HOSPITAL BED UTILIZATION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; SCREENING TEST; STAPHYLOCOCCUS INFECTION; SURGICAL WARD; WOUND DRESSING;

COSTS AND COST ANALYSIS; CROSS INFECTION; DISEASE OUTBREAKS; FINANCIAL MANAGEMENT, HOSPITAL; FINLAND; HOSPITALS, UNIVERSITY; HUMANS; LENGTH OF STAY; MASS SCREENING; METHICILLIN RESISTANCE; PATIENT ISOLATION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WORKLOAD;

EID: 34247477569     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2007.02.014     Document Type: Article

References (19)

1. Abramson M.A., and Sexton D.J. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?. Infect Control Hosp Epidemiol 20 (1999) 408-411
2. Engemann J.J., Friedman J.Y., Reed S.D., et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 26 (2005) 534-539
3. Kopp B.J., Nix D.E., and Armstrong E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 38 (2004) 1377-1382
4. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., and Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
5. McHugh C.G., and Riley L.W. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 25 (2004) 425-430
6. Rao N., Jacobs S., and Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 9 (1988) 255-260
7. Herr C.E., Heckrodt T.H., Hofmann F.A., Schnettler R., and Eikmann T.F. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 24 (2003) 673-678
8. Kim T., Oh P.I., and Simor A.E. The economic impact of methicillin-resistant Staphylococcus aureus Canadian hospitals. Infect Control Hosp Epidemiol 22 (2001) 99-104
9. Papia G., Louie M., Tralla A., Johnson C., Collins V., and Simor A.E. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective?. Infect Control Hosp Epidemiol 20 (1999) 473-477
10. Karchmer T.B., Durbin L.J., Simonton B.M., and Farr B.M. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 51 (2002) 126-132
11. Jernigan J.A., Clemence M.A., Stott G.A., et al. Control of methicillin-resistant Staphylococcus aureus in a university hospital: one decade later. Infect Control Hosp Epidemiol 16 (1995) 686-696
12. Chaix C., Durand-Zaleski I., Alberti C., and Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. J Am Med Assoc 282 (1999) 1745-1751
13. Bjorholt I., and Haglind E. Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis 23 (2004) 688-695
14. Vriens M., Blok H., Fluit A., Troelstra A., Van Der Werken C., and Verhoef J. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 21 (2002) 782-786
15. Tiemersma E.W., Bronswaer S.L., Lyytikainen O., et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 10 (2004) 1627-1634
16. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., and Hughes J.M. CDC definitions. Am J Infect Control 16 (1988) 128-140
17. Graves N., Weinhold D., and Roberts J.A. Correcting for bias when estimating the cost of hospital-acquired infection: an analysis of lower respiratory tract infections in non-surgical patients. Health Econ 14 (2005) 755-761
18. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
19. Bootsma M.C., Diekmann O., and Bonten M.J. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 103 (2006) 5620-5625